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Abstract: For patients awaiting renal transplantation, there is guideline consensus on the 
need for ischemia testing but no agreement on the frequency of repeat testing. Moreover, 
there are no data in this population evaluating changes in ischemia when assessed with 
serial myocardial perfusion imaging. Consecutive ESRD patients (n=649) were referred 
for cardiovascular risk stratification prior to renal transplantation between September 
2007 and September 2013. Of these, 151 (54 ± 9 years, male 63%) underwent two stress-
rest technetium-99m SPECT studies with CT attenuation correction in accordance with 
regional guidelines, which recommend repeat imaging in high-risk subjects who had not 
undergone renal transplantation within 3 years. An abnormal perfusion result was defined 
as a summed stress score  4. The median interval between imaging was 39 months. At 
baseline, 28% of patients (42/151) had abnormal SPECT perfusion, half with a fixed 
defect. Nine subjects (6%) underwent revascularization between imaging studies after the 
baseline SPECT imaging demonstrated an ischemic perfusion defect size (PDS) affecting 
 10% of the myocardium. On repeat imaging, 60% (25/42) had abnormal perfusion. In 
the 72% (109/151) with normal baseline SPECT perfusion, 19% (21/109) demonstrated 
new ischemia at follow-up and 3% (3/109) had an ischemic PDS 10%. The 
development of new-onset ischemia was associated with systolic hypertension (p=0.015), 
serum phosphate (p=0.043) and Agatston score (p=0.002) but not diabetes (p=0.12). In 
conclusion, there is a high frequency of new-onset ischemia in ESRD patients awaiting 
renal transplantation. Further study is needed to define the optimal interval for repeat 
stress testing. 
 
Keywords: End-stage renal disease; myocardial ischemia; SPECT MPI; renal transplant 
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Introduction 
Recent data confirm the prognostic utility of single-photon emission computed 
tomographic (SPECT) imaging in end-stage renal disease (ESRD),1,2 although for patients 
awaiting renal transplantation there remains no guideline consensus on the need for repeat 
stress testing. The National Kidney Foundation recommend annual non-invasive stress 
testing for all patients with diabetes mellitus (DM), and repeating assessments every 24 
months in “high-risk” non-diabetic patients.3 In contrast, the American College of 
Cardiology Foundation emphasizes the lack of evidence that periodic screening of 
asymptomatic subjects awaiting renal transplantation is useful (Class IIb; Level C).4 This 
discrepancy in position statements reflects a paucity of data informing the optimal 
surveillance strategy for subjects awaiting renal transplantation – to date, there are no 
studies that have evaluated serial changes in ischemia as defined by SPECT imaging. 
There is also lack of agreement on which non-invasive imaging modality for 
cardiovascular (CV) risk stratification is most appropriate in ESRD. Most transplant 
centers adopt an imaging strategy according to “best local expertise”, although many 
employ SPECT because of long-term data supporting its prognostic utility in ESRD.5,6 
One disadvantage of serial SPECT is cumulative exposure to radiation,7 which merits a 
concerted effort to identify those patients likely to benefit from repeat testing thereby 
minimizing this long-term hazard. Thus, the aims of this study were to determine: 1) the 
proportion of subjects that develop myocardial perfusion defects while on the waiting list 
for renal transplantation and, 2) the clinical variables that predict new-onset myocardial 
ischemia. 
 
Methods 
Consecutive patients with chronic kidney disease (CKD) stage 4 to 5D (n=649) 
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were referred to Queen Elizabeth Hospital Birmingham for CV risk stratification as part 
of a pre-transplant screening work-up from September 2007 to September 2013. In 
accordance with current guidelines compiled by a Joint Working Party of The British 
Transplantation Society and The Renal Association,8 subjects underwent non-invasive 
CV risk assessment using technetium-99m SPECT studies with CT attenuation correction, 
if they fulfilled any of the following criteria: age >50 years, DM, suspected angina, or 
known ischemic heart disease. Subjects who had not undergone renal transplantation 
within 3 years (n=151) underwent repeat SPECT imaging in accordance with regional 
guidelines and were included in the present analysis (Figure 1). Formal ethical approval 
was not required because this study was a retrospective assessment of solely clinical data 
and was therefore regarded as a health outcomes evaluation. The conduct and reporting of 
this study was guided by the Strengthening the Reporting of Observational Studies in 
Epidemiology statement.9  
Demographic and anthropometric data were collected on all patients through 
review of patient electronic records. In addition, a standard pre-scan assessment involving 
a detailed patient interview was performed to obtain information on symptoms, CV risk 
factors, previous CV events, and medication. A Duke pretest probability of coronary 
artery disease (CAD) was calculated at the time of the imaging study.10 Routine 
hematology and biochemistry indices were also recorded. Diabetes mellitus was defined 
as a fasting glucose >126 mg/dl, history of DM, diabetic nephropathy, or currently 
receiving hypoglycemic treatment. Hypertension was defined as an office blood pressure 
>140/90 mmHg or currently taking anti-hypertensive medication. Hypercholesterolemia 
was defined as a serum cholesterol of >193 mg/dl or currently taking lipid reduction 
therapy. A history of CV disease was defined as having any of the following: CAD 
(myocardial infarction (MI), previous percutaneous, or surgical revascularization), heart 
failure, stroke, and peripheral vascular disease. Significant family history of CV disease 
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was defined as a first degree relative with a history of MI or ischemic stroke in men 
younger than 55 years and in women younger than 65 years. 
The protocol for performing SPECT myocardial perfusion scintigraphy has been 
published.1 Briefly, patients were asked to discontinue beta-blockers, rate-limiting 
calcium channel blockers, and caffeine products 24 hours before testing, and nitrate 
compounds were discontinued >6 hours before testing. All participants underwent 2-day 
stress-rest technetium-99m SPECT imaging with exercise treadmill or standard adenosine 
stress (140 mg/kg/min for 6 minutes) in those unable to achieve 85% maximal heart rate; 
and multi-slice coronary artery calcium scoring (CACS) was performed as routine. CT-
based attenuation correction was performed during reconstruction of the SPECT data 
(Symbia T16, Siemens, Erlangen, Germany). 
SPECT myocardial perfusion images were visually analyzed by 2 experienced 
observers (R.P.S. and B.H.) blinded to the baseline study (Quantitative Perfusion SPECT; 
Hermes Medical Solutions, Stockholm, Sweden). In addition to examination of raw 
images in cine mode, both non-attenuated and attenuated images were reviewed, and a 
report produced consistent with recommendations outlined in the American Society of 
Nuclear Cardiology Imaging Guidelines for Nuclear Cardiology Procedures.11 Short-axis 
and vertical long-axis tomograms were divided into 17 segments for each study,11 and 
segmental tracer uptake was evaluated using a validated semi-quantitative 5-point scoring 
system (0, normal; 1, equivocal; 2, moderate; 3, severe reduction of radioisotope uptake; 
and 4, absence of detectable tracer uptake).12 The summed stress and rest scores were 
obtained by adding the scores of the 17 segments of the respective images. The sum of 
the differences between each of the 17 segments from these images was defined as the 
summed difference score, representing the amount of ischemia. These indexes were 
converted to the percentage of total myocardium involved with stress, ischemic, or fixed 
defects by dividing the summed scores by 68 (the maximum potential score = 4 ×17) and 
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multiplying by 100. The presence of abnormal perfusion was defined as a summed stress 
score of 4 or greater.13 A stress-induced total perfusion defect size (PDS) ≥15% or an 
ischemic PDS ≥10% defined high risk for cardiac events.14 Cardiac volumes and left 
ventricular (LV) ejection fraction were also calculated from the gated SPECT images. 
CACS was calculated according to Agatston et al.15 by the same two independent 
observers. Lesions were manually traced on CT images before semiautomatic 
quantification-derived vessel-specific scores were summated to yield the total CACS 
(syngo.via; Leonardo; Siemens Medical Solutions, Forchheim, Germany). Minimal, mild, 
moderate, and severe coronary calcification were defined as Agatston scores of 0 to 10 U, 
11 to 100 U, 101 to 400 U, and >400 U, respectively.14 
The primary outcome of interest was the development of a new perfusion defect 
between imaging studies. All statistical analyses were performed with SPSS (version 21, 
IBM, Armonk, New York, USA). Data are expressed as mean ± SD, median (interquartile 
range), or frequency (%), unless otherwise stated. The normality of distribution for 
continuous variables was determined using normality plots and the Kolmogorov-Smirnov 
test. Clinical characteristics of subjects with a normal baseline study were examined 
according to their follow up SPECT result. Continuous data were compared using 
independent t tests. Categorical data were compared using a chi-squared analysis or 
Fisher’s exact tests where appropriate. Independent predictors of the development of a 
new perfusion defect were determined using multivariable logistic regression. A 2-tailed 
P<0.05 was considered statistically significant. 
 
Results 
In total, 151 patients (CKD stage 4 to 5D) with serial SPECT/CT studies 
performed between January 2007 and June 2016 were identified (Figure 1). The baseline 
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characteristics of the study cohort are presented in Table 1. The mean age was 54 years, 
63% were male, 39% had DM and 86% had a history of hypertension. The median 
interval between imaging was 39 months (IQR, 30-53 months). Over two-thirds (69%) of 
the cohort had at least mild CACS, and more than a third (35%) had severe CACS (Figure 
2). 
The distribution of myocardial ischemia at baseline and follow up SPECT studies 
is illustrated in Figure 3. At baseline, 28% patients (42/151) had abnormal SPECT 
perfusion, half with a fixed defect. Nine subjects (6%) underwent revascularization in the 
interval between imaging studies, after the baseline SPECT imaging demonstrated an 
ischemic PDS affecting  10% of the myocardium. On repeat imaging, 60% (25/42) still 
had abnormal perfusion, indicating that smaller perfusion defects affecting <10% of the 
myocardium had resolved in 41% (17/42). In 63% (29/46) of the patients with abnormal 
perfusion at follow up, there was an increase in PDS >5%; the mean change in PDS in 
those subjects was 7%. Ten subjects (10/151, 7%) developed new fixed perfusion defects 
(mean PDS 8%), which was associated with a mean reduction in LVEF from 56 to 43%. 
In the 72% (109/151) with a normal baseline SPECT study, 19% (21/109) 
demonstrated new-onset ischemia at follow-up, of which 3% (3/109) had an ischemic 
PDS  10%. Six percent of subjects with a normal baseline perfusion study (6/109) were 
re-classified as “high risk” after developing an ischemic PDS  10% and / or a total PDS 
 15%. Table 2 demonstrates the baseline clinical variables associated with the 
development of new-onset ischemia; these included the presence of chest pain (p=0.048), 
an elevated systolic blood pressure (p=0.015), increased serum phosphate (p=0.043) and 
greater extent of coronary calcification (p=0.002). There was an independent association 
between CACS and the development of a new perfusion defect that remained significant 
after adjustment for age, sex, systolic blood pressure, serum phosphate and presence of 
chest pain (β=0.39, R2=0.5, p<0.001). Although the mean CACS was higher in those 
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subjects that developed new-onset ischemia, there was no threshold CACS observed for 
this effect (Figure 4). More than half the subjects with new-onset ischemia had DM 
(51%) although this result did not reach statistical significance (p=0.12). There was no 
difference in the rates of development of new-onset ischemia between different ethnic 
groups. 
 
Discussion 
This study has demonstrated that almost 20% of ESRD patients awaiting renal 
transplantation develop new-onset myocardial ischemia over a median 3-year interval. 
Risk factors for the development of ischemia included the presence of chest pain, systolic 
hypertension, increased serum phosphate and greater extent of CACS. Relatively few 
subjects (6%) however, developed either an ischemic PDS ≥10% or stress-induced total 
perfusion defect size (PDS) ≥15% over this time-frame sufficient to warrant invasive 
investigation or intervention in the absence of symptoms. Of concern however, a similar 
proportion (7%) developed new fixed perfusion defects, which were associated with a 
mean fall in LVEF of 13%. 
Our data are the first to provide insight into the proportion of subjects with ESRD 
that develop perfusion defects while on the waiting list for renal transplantation. To our 
knowledge, there are only three other studies that have focused on progression of 
ischemia as determined by SPECT.16-18 Two of these were performed in asymptomatic 
patients with DM and akin to our study, approximately 1 in 5 developed abnormal 
perfusion during follow-up ranging from 2-3 years.16,17 In the Detection of Ischaemia in 
Asymptomatic Diabetics (DIAD) study, 358 of the initial 522 patients recruited 
underwent a second SPECT study to evaluate the change in myocardial perfusion at 3 
years.16 In this group, 20% had abnormal baseline perfusion in whom a large proportion 
(79%) then normalized. Comparable results were obtained in a study of 100 
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asymptomatic subjects with type 2 DM, normal resting ECG and no previous history of 
CV disease.17 Again, 20% had abnormal baseline perfusion and a similar percentage 
(65%) then normalized over a shorter period of 2-year follow-up. The assumption made 
in both these studies was that regression of ischaemia was due to improved medical 
therapy, although in the latter, no relationship was found with the addition of anti-anginal 
medication. It is interesting to note that the rate of new-onset ischemia was similar across 
all studies although regression of ischemia was less common in our current ESRD cohort. 
Although no data regarding change in pharmacotherapy or medical management was 
recorded in our study, this lower rate of regression in ischemia may reflect the lack of 
efficacy of standard secondary prevention medication for CV disease in ESRD.19,20 
It is well established that serial myocardial perfusion imaging with SPECT 
provides important information for managing patients with changing clinical presentation 
or, as in our study, in anticipation of such changes.21 A retrospective, longitudinal study 
of 698 patients who had serial SPECT for clinical indications within 16 ± 9 months 
(incorporating 147 subjects with ESRD), identified a significant increase in hard cardiac 
events (death, MI, revascularization) in those with a new perfusion abnormality, increase 
in PDS >5% or a fall in LVEF >5%.18 These data suggest that the changes detected in our 
study are clinically meaningful; the mean change in PDS in subjects with abnormal 
perfusion at follow up in our cohort was 7%, which supports the concept of repeat testing, 
although the optimal frequency cannot be deduced for this specific population. This is 
emphasised by the development of new fixed defects associated with a fall in LV function 
in almost 1 in 20 of our subjects. In our study, the variables associated with the 
development of new-onset of ischaemia included systolic hypertension, increased serum 
phosphate and higher CACS. Patients who developed new-onset ischemia had on average 
greater extent of coronary calcification. There was however, no clear CACS threshold 
below which patients were free from developing abnormal perfusion (Figure 4) with a 
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small but significant proportion of subjects with only minimal coronary calcification 
developed new-onset perfusion defects. In previous research, we identified that abnormal 
perfusion was a more powerful predictor of adverse events than elevated CACS in those 
listed for renal transplantation over a median follow up of 18 months,1 although coronary 
calcification may have more prognostic significance over a longer period of follow-up.22  
The findings of our study are limited by their derivation from a single center and 
the retrospective observational nature of the data. No data were collected on change in 
pharmacotherapy or medical management, which makes it difficult to compare 
differences in the rate of regression of ischaemia with other cohorts. While longitudinal 
studies such as ours have advantages over cross-sectional cohort studies, by default our 
study is at risk of informative censoring, whereby only those patients who survived or 
failed to undergo transplantation could be included in the analysis. Indeed, the selected 
population of patients for this study who did not proceed to transplant are likely at greater 
long-term cardiovascular risk than those who were successfully transplanted.23 A further 
issue is that the variance of the response changes is not known; in other words, the 
variability in SPECT due to technical or biological factors, as well as the intrinsic 
variability of the technique. In this respect, this study has the advantage of being 
performed in the same centre with the same reporting staff and equipment, following 
standardized protocols. Further prospective studies in larger populations that include data 
on intervening management and hard endpoints are still required.4 
In conclusion, there is a high frequency of new-onset ischemia in patients with 
ESRD awaiting renal transplantation, particularly in the presence of systolic hypertension 
and severe coronary calcification. These data support the need for repeat stress testing in 
this high-risk cohort. 
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Figure 1. Study consort diagram.  
Figure 2. Distribution of CACS across the overall cohort. 
Figure 3. Pie charts of the distribution of myocardial ischemia on SPECT stratified 
according to baseline ischemia. Abnormal perfusion was defined as a summed stress 
score of ≥ 4. Data are N (%). Blue represents normal SPECT perfusion; green represents 
abnormal SPECT perfusion. 
Figure 4. Relationship of CACS with the development of new-onset ischemia. 
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Table 1. Baseline demographics and clinical characteristics for study cohort. 
Data are number (%), mean ± SD or median [interquartile range]. 
*Defined as an office blood pressure of > 140/90 mmHg or currently taking hypertensive medications 
†Defined as a fasting serum cholesterol of >193 mg / dL 
Variable n=151 
Age (years) 53.6 ± 9.4 
Men 95 (63%) 
White 80 (53%) 
Asian 55 (36%) 
Black 14 (9%) 
Other ethnicity 2 (1%) 
Body mass index (kg / m
2
) 28.0 ± 7.2 
Diabetes mellitus 59 (39%) 
Diabetes-related treatment  
    Diet-control 4 (3%) 
    Oral hypoglycemic agent 17 (11%) 
    Insulin 38 (25%) 
Hypertension* 131 (86%) 
Hypercholesterolemia† 110 (73%) 
Current smoker 31 (20%) 
Family history of coronary artery disease 5 (3%) 
Number of cardiac risk factors 2.4 ± 1.0 
Previous myocardial infarction 11 (7%) 
Previous percutaneous coronary intervention 13 (9%) 
Previous coronary bypass surgery 9 (6%) 
Previous renal transplant 21 (14%) 
Renal replacement therapy 64 (42%) 
Haemoglobin (g / L) 115.4 ± 15.6 
Total cholesterol (mg / dL) 166 ± 43 
Calcium (mg / dL) 9.00 ± 0.72 
Phosphate (mg / dL) 4.30 ± 1.08 
Parathryoid hormone (pmol / L) [IQR] 22.2 [11.9 – 45.5] 
Estimated Glomerular Filtration Rate (ml / min / 
1.73 m
2
) 
13.4 ± 8.4 
Uric acid (mg / dL) 7.63 ± 2.15 
Medications 
    Aspirin 
 
73 (48%) 
    Thienopyridine 8 (5%) 
    Beta-blocker 53 (35%) 
    ACE inhibitor/angiotensin receptor blocker 87 (58%) 
    Calcium channel blocker 69 (46%) 
    Diuretic 65 (43%) 
    Statin 104 (69%) 
Duke pre-test probability (%) [IQR] 5 (3-8) 
Symptomatic chest pain 35 (23%) 
Ability to perform exercise stress to >85% maximal 
heart rate 
58 (38%) 
Left ventricular ejection fraction (%) [IQR] 56 [50 – 64] 
Abnormal SPECT result (summed stress score ≥4) 42 (28%) 
Summed stress score 2.7 ± 5.3 
Total Perfusion Defect Size (% myocardium) 3.3 ± 8.0 
Ischemic Perfusion Defect Size (% myocardium) 1.7 ± 4.0 
Total Perfusion Defect Size ≥ 15% 11 (7%) 
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Ischemic Perfusion Defect Size ≥ 10% 9 (6%) 
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Table 2. Baseline characteristics of subjects with a normal baseline SPECT study 
stratified according to their follow up perfusion result (n = 109). 
Variable Normal myocardial 
perfusion 
(n = 88) 
Abnormal myocardial 
perfusion 
(n = 21) 
p 
Age (years) 52.9 ± 9.6 50.8 ± 10.6 0.37 
Men 50 (57%) 12 (57%) 0.98 
White 47 (53%) 9 (43%) 0.39 
BMI (kg / m
2
) 28.0 ± 7.1 27.7 ±4.9 0.83 
Diabetes mellitus 30 (34%) 11 (52%) 0.12 
Smoker 40 (45%) 8 (38%) 0.54 
Hypertension 76 (86%) 17 (81%) 0.12 
Hypercholesterolaemia 57 (65%) 11 (52%) 0.29 
Systolic blood pressure (mmHg) 137 ± 23 152 ± 32 0.015 
Symptomatic chest pain 13 (15%) 7 (33%) 0.048 
Duke pre-test probability (%) 6.2 ± 6.1 6.4 ± 5.0 0.89 
Previous renal transplant 12 (14%) 3 (14%) 0.78 
Renal replacement therapy 39 (44%) 8 (38%) 0.65 
Ability to perform exercise stress 31 (35%) 8 (38%) 0.81 
Haemoglobin (g / L) 117 ± 15 114 ± 16 0.43 
Calcium (mg / dL) 9.12 ± 0.76 9.00 ± 0.60 0.52 
Phosphate (mg / dL) 3.84 ± 1.05 4.37 ± 1.05 0.043 
Uric acid (mg / dL) 7.51 ± 2.20 7.65 ± 2.10 0.84 
Coronary artery calcium score (U) 526 ± 61 1404 ± 375 0.002 
Left ventricular ejection fraction 
(%) 
58 ± 12 57 ± 12 0.73 
Data are mean ± SD and N (%). Continuous data are compared using independent t tests. Categorical 
data are compared using a chi-squared analysis. Bold values have a significant p-value (<0.05). 
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